[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cytokines\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cytokines":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100631497","comparison-of-the-effects-of-oral-hygiene-regimens-on-clinical-immunomodulatory-and-microbial-outcomes-and-oral-tolerance-in-people-with-gingivitis-100631497",false,"NCT07501455","Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Outcomes and Oral Tolerance in People With Gingivitis","Inclusion Criteria:\n\n2\\. Adequate oral hygiene (i.e., brush teeth daily and exhibit no signs of gross oral neglect).\n\n3\\. Mean Modified Gingival Index (MGI) is greater than or equal to 2.00 at screening visit and reconfirmed at baseline visit.\n\n4\\. Bleeding upon probing (BOP) is greater than or equal to 30% at the screening visit.\n\n5\\. Diagnosis of gingivitis (confirmed by MGI and BOP) at the screening visit and reconfirmed at the baseline visit.\n\n6\\. Able to read and understand English. 7. Subject has signed the written informed consent (ICD) and indicated their agreement with the terms of the study and the study procedures listed and photograph release including the Health Insurance Portability and Accountability Act (HIPAA) disclosure prior to any study-related procedures.\n\n8\\. Generally, in good overall health based on the medical history reported by the subject.\n\n9\\. Has at least 18 natural teeth (not counting 3rd molars) with scorable facial and lingual surfaces.\n\n10\\. Willingness to use the assigned products according to instructions, availability for appointments, agreement to follow the subject responsibilities and likelihood of completing the clinical trial\n\nExclusion Criteria:\n\n1. Significant oral soft tissue pathology or active dental caries, based on the dentist's visual examination and at the discretion of the Investigator.\n2. History of significant adverse reactions, including sensitivity or suspected allergies, following use of oral hygiene products such as toothpastes, mouth rinses, and red food dye.\n3. Periodontitis, as determined by more than 2 sites with a probing depth greater than 4mm.\n4. Regular consumption of probiotics supplements within one week prior to screening. Subjects can be rescreened if they fulfill this criterion.\n5. Dental prophylaxis within 4 weeks prior to screening. Subjects can be rescreened if they fulfill this criterion.\n6. Subjects who wear orthodontic bands, fixed retainers, removable orthodontic appliances, clear aligners or night guards or subjects who have had significant (based on the examiner or PI's oral exam) cosmetic restorations.\n7. History of medical conditions requiring prophylactic antibiotic coverage prior to dental procedures.\n8. Self-reported tobacco, cannabis, smokeless tobacco use, including snuff, chewing tobacco, vaping, and e-cigarette usage.\n9. Suspected alcohol or substance abuse.\n10. Significant unstable or uncontrolled medical condition which may interfere with a subject's participation in the study, at the discretion of the Investigator, including a history of or a concurrent health\u002Fother condition\u002Fsituation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study.\n11. Has self-reported Type 1 or Type 2 diabetes or is on an anti-diabetic medication (i.e., metformin, insulin, Glucophage, etc.)\n12. Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:\n\n    * Non-steroidal anti-inflammatory drugs within 5 days before Visit 1 (81mg of aspirin is allowed).\\*\n    * Use of Immunosuppressive, or steroidal drugs therapy during the study or within 2 months before Visit 2. \\* Intermittent use (\\\u003C3 times per week) of certain anti-inflammatory medications is acceptable at the discretion of the investigator. Use of anticoagulant therapy within 1 month of screening visit or during the study.\n    * Use of systemic antibiotics within 1 month of screening visit and during the entire study.\n13. Is self-reported to be pregnant, in lactation, planning to become pregnant during the study, or positive pregnancy urine tests (females of child-bearing potential only):\n\n    * For females: Postmenopausal state (i.e., at least 1 year without menses without an alternative medical condition prior to the first study IP administration) or premenopausal\u002Fperimenopausal state with an effective means of contraception.\n    * Females of childbearing potential must be using a medically acceptable method of birth control for at least one month prior to Visit 1 and agree to continue using this method during their participation in the clinical trial. Medically acceptable forms of birth control that may be used by the subject and\u002For his\u002Fher partner include:\n\n      * Double barrier method (condoms, diaphragm or cervical cap with spermicide)\n      * Hormonal prescription contraceptives (i.e., oral, injectable, implanted, patch or vaginal ring hormone therapy)\n      * Intrauterine device (IUD)\n      * Surgical sterilization (e.g., vasectomy that has been confirmed effective by sperm count check, tubal ligation, hysterectomy and\u002For bilateral oophorectomy)\n      * Abstinence\n    * For males: No pregnant or lactating spouse or partner at screening and willingness to utilize an acceptable form of birth control with spouse or any potential partner during the study and for 30 days thereafter.\n14. Participation in any clinical trial within 30 days of the Screening visit.\n15. Subjects who were previously randomized into one of the study products as part of this study.\n16. Subjects who are related to the people who are involved directly or indirectly with the conduct of this study (i.e., principal Investigator, sub-investigators, study coordinators, other site personnel, employees of Kenvue, contractors of Kenvue, and the families of each).\n17. Subjects within the same household as other subjects enrolled in the study at the same time.",true,"ALL","18 Years","60 Years",{"count":20,"type":21},250,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a six-week, double-blind, randomized, parallel-group controlled clinical study. The objective of this study is to evaluate the changes to the oral microbiome, inflammatory mediators, gingival health indices and to assess oral tolerance after 4 weeks of twice daily use of differing oral hygiene regimens including mouthwash compared to a control group. A follow-up assessment will be completed 2 weeks after cessation of treatments.",[27,28,29,30,31],"Microbiome","Cytokines","Plaque","Gingivitis","Gingival Bleeding","RECRUITING","2026-03-26",{"date":35,"type":36},"2026-03-30","ACTUAL",{"date":38,"type":36},"2026-02-26",{"date":40,"type":21},"2026-05-05",{"name":42,"class":43},"Kenvue Brands LLC","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":64,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100583020","impact-of-sarcopenia-on-dyspnea-in-patients-with-asthma-100583020","NCT06870890","Impact of Sarcopenia on Dyspnea in Patients With Asthma","MUDYSA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient affiliated to a social security scheme.\n* Patient capable of giving free, informed, written and signed consent.\n* Asthmatic patients with a diagnosis made by a pulmonologist on GINA level 4 or 5 treatment\n* ACT asthma control score \\\u003C 20\n* Patient judged by the investigator to be able to to perform a maximal exercise test.\n\nExclusion Criteria:\n\n* Patient under guardianship\u002Ftrusteeship\u002Fsupervision of justice\n* Pregnant or breast-feeding women\n* Unstable heart disease\n* Patients who have been smoking or have stopped smoking for less than 5 years,",{"count":53,"type":21},100,[24],"Dyspnea in asthma, is mainly due to airway obstruction but can be caused by several alternative diagnoses.\n\nThe impact of sarcopenia on dyspnea in patients with asthma is unknown. Sarcopenic asthma had a reduced physical activity and is associated with airway obstruction compared to non-sarcopenic asthma. In patients with obstructive pulmonary disease, sarcopenia is associated with shallow breathing and diverse sensory and affective components of exertional dyspnea .\n\nThe morbidity of sarcopenia is also increased by systemic inflammation and the production of inflammatory cytokines as found in inflammatory airway obstruction.\n\nThe investigators will investigate the prevalence and impact of sarcopenia in asthmatics patients. This will enable to better manage sarcopenia in asthmatic patients, understand its origins and personalize treatment.",[57,58,59,60,28,61,62,63],"Sarcopenia","Asthma","Dyspnea","Dyspnea; Asthmatic","Adipokines","Myokine","Muscle Disorder",[58,57,59],"NOT_YET_RECRUITING","2025-03-10",{"date":68,"type":36},"2025-03-11",{"date":70,"type":21},"2025-03-25",{"date":72,"type":21},"2026-10",{"name":74,"class":75},"University Hospital, Clermont-Ferrand","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":44},"100534797","comparison-of-cytokines-profile-in-aqueous-humor-and-tear-before-and-after-ucp-treatment-100534797","NCT06243497","Comparison of Cytokines Profile in Aqueous Humor and Tear Before and After UCP Treatment","Inclusion Criteria:\n\n* The patient was definitely diagnosed as glaucoma, No age or gender limitation, IOP(intraocular pressure) ≥ 21mmHg under the maximum tolerated dose of antiglaucoma medication, or IOP \\\u003C 21mmHg and glaucomatous optic nerve damage progressed.\n\nExclusion Criteria:\n\n* Other eye diseases that could affect IOP; preoperative use of systemic steroid drugs; history of other anti-glaucoma surgery within 3 months; ocular infection 2 weeks prior to UCP",{"count":83,"type":21},200,"OBSERVATIONAL","Glaucoma is the leading cause of irreversible vision loss in people aged 50 years and older worldwide, second only to cataracts. Ultrasound Cyclo Plasty was first proposed as a new minimally invasive technique in the 1980 s. In recent years, many clinical studies at home and abroad have confirmed the effectiveness, safety and repeatability of UCP. The ciliary body is the target organ of UCP, and the range and accuracy of intraoperative destruction of the ciliary body are the key factors affecting the success or failure of the operation. The production of aqueous humor is closely related to the ciliary body. The dynamic balance of its production and discharge can affect IOP, and its content can directly reflect the intraocular environment. Besides,tears are easy to collect and can be used for follow-up. Previous studies have shown that various proteins in aqueous humor or tear can provide a basis for the pathophysiological changes of glaucoma, and can also be a potential biomarker for predicting the success of anti-glaucoma surgery.\n\nAt present, UCP related research focuses on its effectiveness and safety, mainly reflected in three aspects : postoperative intraocular pressure, number of anti-glaucoma drugs and complications, and lack of relevant indicators that directly reflect postoperative intraocular environment changes. The purpose of this study was to reveal the changes of cytokines in aqueous humor after UCP in patients with primary glaucoma, to analyze the possible causes of these factors, and to speculate the effect of their interaction on the surgical effect, in order to increase the predictability of UCP procedure.",[87,88,89,90,28],"Glaucoma","Ultrasound Cyclo Plasty","Aqueous Humor","Tear","2024-02-01",{"date":93,"type":36},"2024-02-06",{"date":91,"type":21},{"date":96,"type":21},"2027-02-01",{"name":98,"class":75},"Zhongshan Ophthalmic Center, Sun Yat-sen University"]